macimorelin acetate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
macimorelin acetate: clinical details
Prescribing considerations
- Diagnostic use only; testing must be supervised by a clinician experienced in diagnosing growth hormone deficiency.
- Confirm fasting status, absence of recent strenuous exercise, and a complete medicines and herbal-products history.
- Interpret the response within the full diagnostic work-up rather than in isolation.
- Diagnostic performance is not established for severe obesity, adults older than 65 years, children, or people with renal or hepatic impairment.
- Correct other pituitary hormone deficiencies appropriately before testing. Hypercortisolism or supraphysiological glucocorticoid exposure may cause misleading results.
- Recent-onset hypothalamic disease can produce a false-negative result because macimorelin acts downstream of the hypothalamus.
Contraindications and cautions
- Hypersensitivity to macimorelin acetate or any excipient.
- Use in congenital or acquired long-QT syndrome or previous torsades de pointes should only be considered in an appropriate cardiovascular clinical unit.
- The formulation contains lactose; assess suitability in relevant rare hereditary carbohydrate-intolerance disorders.
Monitoring
- Obtain growth hormone samples according to the product-specific testing protocol and use the validated assay interpretation pathway.
- Consider ECG assessment in patients with proarrhythmic conditions, significant cardiac disease, renal or hepatic impairment, or other factors increasing macimorelin exposure.
- Monitor clinically for dizziness, palpitations, bradycardia or other possible rhythm-related symptoms.
Clinical pharmacology
Macimorelin is an orally active peptidomimetic ghrelin agonist that activates growth hormone secretagogue receptors in the pituitary and hypothalamus. It is rapidly absorbed, primarily metabolised by CYP3A4 and can modestly prolong the corrected QT interval.
Formulation and product differences
- The selected product is supplied as granules in a sachet for preparation as an oral suspension.
- The suspension must be prepared and administered by a healthcare professional and used promptly after preparation.
- The product contains lactose and is essentially sodium-free. Unopened sachets require refrigerated storage and protection from light and moisture.
macimorelin acetate preparations and strengths
Oral suspension
Route: Oral
Strengths: 60 mg
macimorelin acetate interactions
Some medicines can alter the growth hormone response, change macimorelin exposure or increase cardiac risk. Do not stop medicines yourself; give the testing team a complete list in advance.
Strong CYP3A4 inducers, including carbamazepine, phenytoin, rifampicin and St John’s wort
They can reduce macimorelin exposure and may produce a misleading result suggesting growth hormone deficiency.
Strong CYP3A4 or P-glycoprotein inhibitors
They may increase macimorelin exposure, with uncertain effects on QT-related cardiac risk.
Growth hormone and medicines affecting its release, including somatostatin analogues, clonidine, levodopa, insulin, glucocorticoids and atropine
They can increase or suppress the growth hormone response and make the result unreliable.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.